Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL COMPOUND versus ROBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL COMPOUND versus ROBAXIN.
CARISOPRODOL COMPOUND vs ROBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
None Documented
None Documented
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant